Home|Prescribing Information|Contact Us|Site Map
About CPP

Central precocious puberty, or CPP, is the term for puberty that starts earlier than usual. That is, before age 8 in girls or age 9 in boys. CPP can even begin in infancy. The condition occurs in 1 out of every 5,000 to 10,000 children, and is much more common in girls than in boys (10 to 1).

In most cases, the cause of CPP is unknown (called “true” CPP). Fortunately, today’s medicines, called GnRH agonists, can stop the progression of early puberty associated with CPP.

Some children (usually boys) have an underlying problem that is causing the signs of puberty. The diagnostic tests for CPP will determine if an underlying problem exists. If so, the problem is treated directly in order to stop the progression of early puberty.

Register with SUPPRELIN LA

Indication

SUPPRELIN® LA (histrelin acetate) implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.

Endo Pharmaceuticals
Rx Only
© 2010 Endo Pharmaceuticals. All rights reserved.
SUPPRELIN® LA is a registered trademark of Endo Pharmaceuticals.
SP-1007/June 2009

Privacy/Legal
Intended for U.S. Residents Only